Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) EBITDA (2016 - 2025)

Vycor Medical has reported EBITDA over the past 16 years, most recently at -$62686.0 for Q4 2025.

  • Quarterly EBITDA fell 830.47% to -$62686.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$72426.0 through Dec 2025, up 32.44% year-over-year, with the annual reading at -$72426.0 for FY2025, 32.44% up from the prior year.
  • EBITDA was -$62686.0 for Q4 2025 at Vycor Medical, down from $4936.0 in the prior quarter.
  • Over five years, EBITDA peaked at $68408.0 in Q2 2023 and troughed at -$242912.0 in Q1 2021.
  • The 5-year median for EBITDA is -$45233.5 (2023), against an average of -$54494.4.
  • Year-over-year, EBITDA crashed 3205.38% in 2022 and then soared 337.97% in 2025.
  • A 5-year view of EBITDA shows it stood at -$187063.0 in 2021, then surged by 37.7% to -$116548.0 in 2022, then rose by 20.16% to -$93055.0 in 2023, then skyrocketed by 92.76% to -$6737.0 in 2024, then tumbled by 830.47% to -$62686.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's EBITDA are -$62686.0 (Q4 2025), $4936.0 (Q3 2025), and $23887.0 (Q2 2025).